Analytical Chemistry · 2012 · 70 citations · 28 references
PharmacyBiotechnologyMolecular BiologyMass Spectrometric AnalysisMonoclonal AntibodiesProteomicsAntibody CharacterizationAntibody DiscoveryBioanalytical Method ValidationPeptide AnalysisTargeted ProteomicsBioanalysis Of Monoclonal AntibodiesLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisLiquid Chromatography-mass Spectrometry Method DevelopmentLower Limit Of QuantificationLower Limit Of QuantitationMonoclonal Antibody DiscoverySelected Reaction Monitoring
Although liquid chromatography/mass spectrometry using selected reaction monitoring (LC/SRM-MS) holds great promise for targeted protein analysis, quantification of therapeutic monoclonal antibody (mAb) in tissues represents a daunting challenge due to the extremely low tissue levels, complexity of tissue matrixes, and the absence of an efficient strategy to develop an optimal LC/SRM-MS method. Here we describe a high-throughput, streamlined strategy for the development of sensitive, selective, and reliable quantitative methods of mAb in tissue matrixes. A sensitive nano-LC/nanospray-MS method was employed to achieve a low lower limit of quantification (LOQ). For selection of signature peptides (SP), the SP candidates were identified by a high-resolution Orbitrap and then optimal SRM conditions for each candidate were obtained using a high-throughput, on-the-fly orthogonal array optimization (OAO) strategy, which is capable of optimizing a large set of SP candidates within a single nano-LC/SRM-MS run. Using the optimized conditions, the candidates were experimentally evaluated for both sensitivity and stability in the target matrixes, and SP selection was based on the results of the evaluation. Two unique SP, respectively from the light and heavy chain, were chosen for quantification of each mAb. The use of two SP improves the quantitative reliability by gauging possible degradation/modification of the mAb. Standard mAb proteins with verified purities were utilized for calibration curves, to prevent the quantitative biases that may otherwise occur when synthesized peptides were used as calibrators. We showed a proof of concept by rapidly developing sensitive nano-LC/SRM-MS methods for quantifying two mAb (8c2 and cT84.66) in multiple preclinical tissues. High sensitivity was achieved for both mAb with LOQ ranged from 0.156 to 0.312 μg/g across different tissues, and the overall procedure showed a wide dynamic range (≥500-fold) and good accuracy [relative error (RE) < 18.8%] and precision [interbatch relative standard deviation (RSD) < 18.1%, intrabatch RSD < 17.2%]. The quantitative method was applied to a comprehensive investigation of the steady-state tissue distribution of 8c2 in wild-type mice versus those deficient in FcRn α-chain, FcγIIb, and FcγRI/FcγRIII, following a chronic dosing regimen. This work represents the first extensive quantification of mAb in tissues by an LC/MS-based method.
28
Monoclonal antibody successes in the clinic
Janice M. Reichert, Clark Rosensweig, Laura Faden et al. · Nature Biotechnology · 2005 · 727 citations
Computational prediction of proteotypic peptides for quantitative proteomics
Parag Mallick, Markus Schirle, Sharon S. Chen et al. · Nature Biotechnology · 2006 · 694 citations
Hasmik Keshishian, Terri A. Addona, Michael Burgess et al. · Molecular & Cellular Proteomics · 2007 · 680 citations · Full text